The diffusion of the SARS‐CoV‐2 virus and the implementation of restrictive measures led to
a drastic reduction of respiratory syncytial virus (RSV) diffusion. Few RSV cases have been …

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease in
young children and elderly people. Although the virus was isolated in 1955, an effective …

Human respiratory syncytial virus (RSV) belongs to the recently defined Pneumoviridae
family, Orthopneumovirus genus. It is a negative sense, single stranded RNA virus that …

Respiratory syncytial virus (RSV) is a single-stranded negative-sense RNA virus that is the
primary etiologic pathogen of bronchitis and pneumonia in infants and the elderly. Currently …

The RSVPreF3-AS01 vaccine, containing the respiratory syncytial virus (RSV) prefusion F
protein and the AS01 adjuvant, was previously shown to boost neutralization responses …

In 2022, Austria experienced a severe respiratory syncytial virus (RSV) epidemic with an
earlier‐than‐usual start (Weeks 35/2021–45/2022) and increased numbers of pediatric …

Viruses that emerge pose challenges for treatment options as their uniqueness would not
know completely. Hence, many viruses are causing high morbidity and mortality for a long …

Respiratory syncytial virus (RSV) is a common respiratory pathogen that causes mild cold-
like symptoms and severe lower respiratory tract infections, causing hospitalizations in …

Since the first human respiratory syncytial virus (HRSV) genotype classification in 1998,
inconsistent conclusions have been drawn regarding the criteria that define HRSV …

Introduction Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory
tract infection (LRTI) in infants and young children. Palivizumab is an RSV-specific …